FULCRUM THERAPEUTICS INC (FULC)       7.28  -0.54 (-6.91%)

Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid and robust increases in hemoglobin F (HbF); supports...

Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Fulcrum Therapeutics Announces Departure of Chief Medical Officer

CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the...

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Friday Sector Laggards: Biotechnology, Drugs

Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial

- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports...

Notable Tuesday Option Activity: GOOG, FULC, LOVE

Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria

- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability,...

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

– Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress – – Phase 3 REACH trial of losmapimod...

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...